二次怀孕期间乙型肝炎病毒的抗病毒治疗。

StephenW

J Obstet Gynaecol Res. 2017 Dec 11. doi: 10.1111/jog.13540. [Epub ahead of print]
Antiviral therapy for hepatitis B virus during second pregnancies.Wakano Y1, Sugiura T1, Endo T1, Ito K1, Suzuki M2, Tajiri H3, Tanaka Y4, Saitoh S1.
Author information
1Department of Pediatrics and Neonatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.2Department of Pediatrics, Juntendo University Graduate School of Medicine, Tokyo, Japan.3Department of Pediatrics, Osaka General Medical Center, Osaka, Japan.4Department of Virology and Liver Unit, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.

AbstractMother-to-child transmission of the hepatitis B virus (HBV) is a major concern for infected mothers, especially after their first child has become an HBV carrier despite immunoprophylaxis. Eight mothers whose first child had become an HBV carrier despite immunoprophylaxis were referred for antiviral therapy during the subsequent pregnancy. All pregnant women were seropositive for both the hepatitis B surface antigen and hepatitis B e antigen. In the treatment group (three receiving lamivudine and two receiving tenofovir), mother-to-child transmission of the HBV was successfully prevented in all infants (5/5). On the other hand, two of three infants became HBV carriers in the untreated group. There were no significant adverse effects in either mothers or infants. Antiviral therapy using lamivudine and tenofovir during the second pregnancy successfully prevented mother-to-child transmission of the HBV for high-risk mothers.


KEYWORDS: hepatitis B virus; lamivudine; mother-to-child transmission; pregnancy; tenofovir

PMID:29227001DOI:10.1111/jog.13540

StephenW

J Obstet Gynaecol Res。 2017年12月11日doi：10.1111 / jog.13540。 [电子版提前打印]
二次怀孕期间乙型肝炎病毒的抗病毒治疗。
Wakano Y1，Sugiura T1，Endo T1，Ito K1，Suzuki M2，Tajiri H3，Tanaka Y4，Saitoh S1。
作者信息

1
    日本名古屋市名古屋市大学医学研究科小儿科和新生儿科。
2
    日本东京Juntendo大学医学研究科小儿科。
3
    日本大阪大阪综合医疗中心小儿科。
4
    日本名古屋市名古屋市大学医学研究科病毒学与肝脏科。

抽象

乙型肝炎病毒（HBV）母婴传播是受感染母亲的一个主要问题，尤其是在第一个孩子成为乙肝病毒携带者后，尽管有免疫预防措施。第一个孩子在免疫预防后成为HBV携带者的八位母亲在随后的怀孕期间接受了抗病毒治疗。所有孕妇对乙型肝炎表面抗原和乙型肝炎e抗原均呈血清阳性。在治疗组（3名接受拉米夫定和2名接受替诺福韦），成功阻止了所有婴儿的母婴传播（5/5）。另一方面，三名婴儿中的两名在未治疗组中成为HBV携带者。对母亲或婴儿都没有明显的不良影响。在第二次怀孕期间使用拉米夫定和替诺福韦的抗病毒治疗成功地阻止了高危母亲的母婴传播。
关键词：

乙肝病毒;拉米夫定;母婴传播;怀孕;替诺福韦

结论：
    29227001
DOI：
    10.1111 / jog.13540